Phase 2 Start
VOGX: Phase 2 Start: Phase 2B Randomized, Placebo-Controlled, Double-Blind, Repeat Dose Parallel Study in Participants Wi
October 1, 2026 · post-bariatric. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- October 1, 2026
- Company
- Vogenx, Inc. (VOGX)
- Drug
- post-bariatric
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 2 Start~month
Phase 2 Start: Phase 2B Randomized, Placebo-Controlled, Double-Blind, Repeat Dose Parallel Study in Participants Wi
- Company
- Vogenx, Inc. (VOGX)
- Drug
- post-bariatric
- Indication
- Postbariatric Hypoglycemia